Clinical Trials Logo

Chronic Migraine clinical trials

View clinical trials related to Chronic Migraine.

Filter by:

NCT ID: NCT06461767 Recruiting - Chronic Migraine Clinical Trials

Repetitive Transcranial Magnetic Stimulation in Treatment and Prophylaxis of Chronic Migraine in Patients With no Prophylactic Treatment for the Last 3 Months

rTMS
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

Compared with the patients with episodic migraine those with chronic migraine have worst quality of life and more severe headache related disability we investigate Repetitive transcranial magnetic stimulation in treatment and prophylaxis of chronic migraine

NCT ID: NCT06450444 Not yet recruiting - Chronic Migraine Clinical Trials

Randomized, Double-blind, Sham-controlled Trial to Investigate Combined Occipital and Supra-orbital Neuromodulation in Resistant Migraine.

RECLAIM
Start date: June 24, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and performance, including clinical benefit, of the PRIMUS System for the treatment of Resistant Migraine.

NCT ID: NCT06428838 Not yet recruiting - Migraine Clinical Trials

Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context

Start date: September 30, 2024
Phase: Phase 3
Study type: Interventional

The purpose of the study is to investigate how a medication called eptinezumab (Vyepti) given to patients in the Emergency Department (ED) might help prevent migraines from happening again. The results of this study may help inform better ways to manage patients with migraines in the ED. Eptinezumab is currently approved by Health Canada for the preventive treatment of migraine, but its short-term effectiveness in the ED context is unknown. Unlike other migraine treatments used in the ED, eptinezumab can rapidly interrupt the migraine process, potentially also preventing migraine from coming back in the short term. Most patients with a diagnosis of migraine have no access to preventative therapies. This study will be able to provide access to preventative therapy at the earliest stages of a migraine attack. Administering this medication in the ED may stop the attack more effectively compared to current therapies. This study wants to see if eptinezumab could help stop migraines from coming back after individuals have been treated in the ED. The study will also explore whether eptinezumab could reduce how often individuals with migraine might need to come back to the ED, what other medications they might need alongside eptinezumab, and how they feel overall.

NCT ID: NCT06414044 Recruiting - Migraine Clinical Trials

Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients

STAR
Start date: May 9, 2024
Phase:
Study type: Observational

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of atogepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.

NCT ID: NCT06409845 Recruiting - Migraine Clinical Trials

Effectiveness and Tolerability of Eptinezumab

TACHIS
Start date: March 26, 2024
Phase:
Study type: Observational

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of eptinezumab as preventive migraine treatment in a cohort of episodic or chronic migraine patients.

NCT ID: NCT06409832 Recruiting - Migraine Clinical Trials

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

RAISE
Start date: March 26, 2024
Phase:
Study type: Observational [Patient Registry]

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.

NCT ID: NCT06322407 Not yet recruiting - Chronic Migraine Clinical Trials

Ultrasound-guided Stellate Ganglion Block for Treatment of Chronic Migraine in Adult

Start date: June 2024
Phase: N/A
Study type: Interventional

To assess the 6-months effects and safety of stellate ganglion block(SGB) for Chronic Migraine (CM) patients who failure to undergo preventive therapy and are seeking a more suitable non-pharmacological therapy.

NCT ID: NCT06309251 Recruiting - Clinical trials for Autism Spectrum Disorder

Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients

Start date: March 1, 2022
Phase:
Study type: Observational

The goal of this observational study is to learn about the clinical and nutritional effectiveness of ketogenic diet (KD) in pediatric patients with genetic, neurological or metabolic conditions requiring KD. The main question[s] it aims to answer are: - does KD support adequate growth? - does KD improve clinical symptoms? - how does KD impact quality of life? Participants will be followed up as per clinical practice

NCT ID: NCT06219694 Completed - Chronic Migraine Clinical Trials

Laser Acupuncture for Chronic Migraine

LAFCM
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

A single-blind randomized controlled trial was conducted from January 2022 to September 2023. Chronic migraine patients were randomly assigned in a 1:1 ratio to receive either Laser acupuncture or sham treatment. The co-primary outcomes were changes in monthly migraine days (MMD) and acute headache medications usage days per month from baseline. Evaluations were taken at baseline and each follow-up point.

NCT ID: NCT06170281 Recruiting - Migraine Clinical Trials

Sequential, Multiple Assignment, Double Randomized Preference, Migraine Behavioral Trial

SMARTMig
Start date: December 15, 2023
Phase: N/A
Study type: Interventional

This study will unpack the behavioral intervention for migraine and determine the optimum combinations. In addition, the study will test preference and self-selection effects during the trial.